Skip to main content

Advertisement

SpringerLink
Log in

Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Corticosteroid-resistant graft-versus-host disease (GvHD) is difficult to manage and is associated with high morbidity and mortality. The purpose of our study was to evaluate the safety and efficacy of mycophenolate mofetil (MMF) as the salvage therapy for steroid-refractory GvHD. Twenty one patients (10 with acute GvHD and 11 with chronic GvHD) were studied retrospectively. Steroid-resistant GvHD was defined as acute or chronic GvHD not responding to a first-line regimen of cyclosporine A and corticosteroids in a dose equivalent to 2 mg/kg methylprednisolone for at least 7 days. MMF was added at a dose of 2 g daily, and corticosteroids were tapered. Thirteen (62%) of 21 patients responded to the treatment with MMF, including 6 (60%) of 10 patients with acute refractory GvHD and 7 (64%) of 11 patients with chronic refractory GvHD. The most common adverse effects were infectious complications (67%, 14 of 21 patients) and hematological toxicity (29%, 6 of 21 patients). Median duration of MMF administration was 6 months (range 1–27 months). Sixteen of 21 patients were alive after the median follow-up of 27 months (range 1–72 months) after the initiation of MMF therapy. All 16 surviving patients were in good clinical condition and in remission of their hematological malignancy. Five patients died—two of relapses of leukemia and three of refractory intestinal GvHD. These results suggest that MMF can be an effective treatment for some cases of steroid-refractory GvHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anasetti C, Hansen JA (1994) Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors. Transfus Sci 15:221–230

    Article  CAS  PubMed  Google Scholar 

  2. Lazarus HM, Vogelsang GB, Rowe JM (1997) Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 19:577–600

    Article  CAS  PubMed  Google Scholar 

  3. Deeg HJ (1994) Prophylaxis and treatment of acute graft-versus-host disease: current state, implications of new immunopharmacologic compounds and future strategies to prevent and treat acute GVHD in high-risk patients. Bone Marrow Transplant 14(Suppl 4):S56–S60

    PubMed  Google Scholar 

  4. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N (2002) Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 30:287–295

    Article  CAS  PubMed  Google Scholar 

  5. Schiller G, Gale RP (1993) Is there an effective therapy for chronic graft-versus-host disease? Bone Marrow Transplant 11:189–192

    CAS  PubMed  Google Scholar 

  6. Mookerjee B, Altomonte V, Vogelsang G (1999) Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant 24:517–520

    Article  CAS  PubMed  Google Scholar 

  7. Vogelsang GB (2001) How I treat chronic graft-versus-host disease. Blood 97:1196–1201

    Article  CAS  PubMed  Google Scholar 

  8. Allison AC, Eugui EM (1996) Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 10:77–84

    CAS  PubMed  Google Scholar 

  9. Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225–243

    CAS  PubMed  Google Scholar 

  10. Kobashigawa J, Miller L, Renlund D, Mentzer R, Alderman E, Bourge R, Constanzo M, Eisen H, Dureau G, Ratkovec R, Hummel M, Ipe D, Johnson J, Keogh A, Mamelok R, Mancini D, Smart F, Valantine H (1998) A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Transplantation 66:1395–1398

    PubMed  Google Scholar 

  11. Basara N, Blau WI, Kiehl MG, Romer E, Rudolphi M, Bischoff M, Kirsten D, Sanchez H, Gunzelmann S, Fauser AA (1998) Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipients. Transplant Proc 30:4087–4089

    Article  CAS  PubMed  Google Scholar 

  12. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, Thomas ED (1995) Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825–828

    CAS  PubMed  Google Scholar 

  13. Abhyankar S, Godder K, Christiansen N (1998) Treatment of resistant acute and chronic graft versus host disease with mycophenolate mofetil. Blood 92:Abstr. 4467

    Google Scholar 

  14. Redei I, Langston AA, Cherry JK (1999) Salvage therapy with mycophenolate mofetil (MMF) for patients with severe chronic GVHD. Blood 94:Abstr. 698

    Google Scholar 

  15. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, Lee KB (2004) Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 73:56–61

    Article  CAS  PubMed  Google Scholar 

  16. Sullivan KM (1994) Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds) Bone marrow transplantation. Blackwell, Oxford, pp 339–362

    Google Scholar 

  17. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102:2768–2776

    Article  CAS  PubMed  Google Scholar 

  18. Sato T, Sakamaki S, Nagaoka Y, Kuribayashi K, Nagamachi Y, Morii K, Honma H, Kogawa K, Kato J, Niitsu Y (1997) Intra-mesenteric artery steroid administration relieved severe refractory gastro-intestinal graft-vs.-host disease in an allogeneic bone marrow transplantation patient. Am J Hematol 56:277–280

    Article  CAS  PubMed  Google Scholar 

  19. Shapira MY, Bloom AI, Or R, Sasson T, Nagler A, Resnick IB, Aker M, Ziberman I, Slavin S, Verstanding A (2002) Intra-arterial catheter directed therapy for severe graft-versus-host disease. Br J Haematol 119:760–764

    Article  CAS  PubMed  Google Scholar 

  20. Mayer J, Krejci M, Doubek M, Pospisil Z, Brychtova Y, Tomiska M, Racil Z (2005) Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 35:699–703

    Article  CAS  PubMed  Google Scholar 

  21. McCaul KG, Nevill TJ, Barnett MJ, Toze CL, Currie CJ, Sutherland HJ, Conneally EA, Sheperd JD, Nantel SH, Hogge DE, Klingemann HG (2000) Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin. J Hematother Stem Cell Res 9:367–374

    Article  CAS  PubMed  Google Scholar 

  22. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, Westervelt P, Trinkaus K, Goodnough LT, Hayashi RJ, Parker P, Forman SJ, DiPersio JF (2001) Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 27:1059–1064

    Article  CAS  PubMed  Google Scholar 

  23. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O (2001) Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin. Clin Transplant 15:147–153

    Article  CAS  PubMed  Google Scholar 

  24. Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB (2002) Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 8:155–160

    Article  PubMed  Google Scholar 

  25. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, Storb R, Hansen JA (1991) A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77:1821–1828

    CAS  PubMed  Google Scholar 

  26. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH (2004) Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104:1224–1226

    Article  CAS  PubMed  Google Scholar 

  27. Hsu B, May R, Carrum G, Krance R, Przepiorka D (2001) Use of antithymocyte globulin for treatment of steroid-refractory acute graft-versus-host disease: an international practice survey. Bone Marrow Transplant 28:945–950

    Article  CAS  PubMed  Google Scholar 

  28. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R (2002) Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 30:899–903

    Article  CAS  PubMed  Google Scholar 

  29. Basara N, Kiehl MG, Blau W, Romer E, Bischoff M, Schmetzer B, Kirsten D, Gunzelmann S, Fauser AA (2001) Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc 33:2121–2123

    Article  CAS  PubMed  Google Scholar 

  30. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S (2000) Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95:83–89

    CAS  PubMed  Google Scholar 

  31. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan KM, Witherspoon R, Deeg HJ (2001) Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72:1924–1929

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine—Hematooncology, Masaryk University Hospital, Jihlavska 20, Brno, 625 00, Czech Republic

    Marta Krejci, Michael Doubek, Tomas Buchler, Yvona Brychtova, Jiri Vorlicek & Jiri Mayer

Authors
  1. Marta Krejci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Doubek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomas Buchler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yvona Brychtova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiri Vorlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiri Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marta Krejci.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krejci, M., Doubek, M., Buchler, T. et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 84, 681–685 (2005). https://doi.org/10.1007/s00277-005-1070-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1070-0

Keywords

Search

Navigation